EULAR 2023: Featured Industry Presentations Save

Jack Cush, MD

May 30, 2023 3:13 pm

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023.

You can search the EULAR site for these abstracts and other research that may interest you - click here.

Abbvie

Industry Sponsor	Abstract #	Date	Presentation Title
Abbvie	POS0849	Thurs, 1 June; 14:45-15:45 CEST	Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Five-Year Data From the SELECT-COMPARE Study
	POS1541	Sat, 3 June; 10:30-11:30 CEST	Long-Term Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: Three-Year Results from the Phase 3 SELECT-PsA 1 Study
	POS1122	Fri, 2 June; 9:30-10:30 CEST	Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis and an Inadequate Response to Biologic DMARD Therapy: One-Year Results from a Phase 3 Study
	OP0139		A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek)

Industry Sponsor	Abstract #	Date	Presentation Title
BMS	POP0130	Thurs, 1 June	ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL

Industry Sponsor	Abstract #	Date	Presentation Title
UCB	POS0231	Friday, June 2, 12:00–13:30 CEST	Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE study and its open-label extension up to 1 year
	POS0246	Friday, June 2, 12:00–13:30 CEST	Bimekizumab reduced MRI inflammatory lesions in patients with axial spondyloarthritis: Week 52 results from the BE MOBILE 1 and BE MOBILE 2 phase 3 studies
	POS1537	Saturday, June 3, 10:30–11:30 CEST	Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active-reference study BE OPTIMAL
	POS0115	Thursday, June 1, 12:00–13:30 CEST	Dapirolizumab pegol efficacy by subgroups in patients with systemic lupus erythematosus: A post hoc analysis of phase 2 clinical trial data

Industry Sponsor	Abstract #	Date	Presentation Title
Horizon	OP0143	June 1, 11:35-11:45 a.m. CEST	Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Subjects with Sjögren’s Syndrome: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study